
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
This trial compared doxorubicin or a combination of docetaxel and gemcitabine as the first treatment for advanced soft tissue sarcoma. It was for people whose sarcoma had spread into the surrounding body tissue, or to other parts of the body.
The trial closed in 2014 and these results were published in 2017.
Cancer Research UK supported this trial.
The trial team found that doxorubicin should remain as the standard first treatment for people with advanced soft tissue sarcoma.
This phase 3 trial recruited 257 people. It was a randomised trial. Those taking part were put into 1 of 2 treatment groups.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Beatrice Seddon
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University College London (UCL)
This is Cancer Research UK trial number CRUK/10/004.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”